

CONNECT medical expert forum speaker biography



Tetsuhide Ito, MD, PhD
Kyushu University, Fukuoka, Japan

Dr Tetsuhide Ito is Associate Professor at the Pancreatic Diseases Branch at Kyushu University in Fukuoka, Japan. His research interests focus on neuroendocrine tumors, pancreatic tumors and pancreatitis. Dr Ito has published widely in peer-reviewed journals.

Dr Ito graduated from Kyushu University in medicine in 1984, later specializing in pancreatology mainly working at Kyushu National Cancer Center and Kyushu University. In 1993, he acquired a Ph.D. (Doctor of Medical Science) and became assistant professor at Kyushu University Hospital. 1996 he worked at National Institute of Health (NIH) for three years, where Dr. Robert T Jensen was his director at Digestive Disease Branch, NIH in the USA for work on gastrointestinal and pancreatic neuroendocrine tumors, especially research on PACAP and VIP. Since then, Dr Ito and Dr Jensen collaborate lots of clinical and basic researches in the fields of neuroendocrine tumors.

In 2000, Dr Ito became a chief of Pancreatic Disease Branch at Kyushu University and in 2010 he became associate professor. Recently, he conducted the nationwide survey of neuroendocrine tumors for the first time in Japan. Further, he participated in phase III global RADIANT-3 study, phase II global Cooperative Study, phase III global RADIANT-4 study, and so on. Especially his institute enrolled 21 patients in RADIANT-3. He is associate editor of Journal of Gastroenterology and advisory board of ENETS.

Recent his articles concerning with neuroendocrine tumors are as follows:

- 1) Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. *Int J Endo Oncol.* 2016;3(1):53-66.
- 2) Ito T, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. *J Gastroenterol.* 2015;50(1):58-64.
- 3) Ito T, et al. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan. *J Hepatobiliary Pancreat Sci.* 2015;22(8):574-7.
- 4) Ito T, et al. Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1 With Pancreatic Endocrine Tumor and Zollinger-Ellison Syndrome: Prospective Study of 106 Cases and Review of the Literature. *Medicine (Baltimore).* 2013;92(3):135-81.
- 5) Ito T, et al. Phase II Study of Sunitinib in Japanese Patients with Unresectable or Metastatic, Well-differentiated Pancreatic Neuroendocrine Tumor. *Invest New Drugs.* 2013;31(5):1265-74.
- 6) Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. *J Gastroenterol.* 2012;47(9):941-60.
- 7) Yao JC, Shah MH, Ito T, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors *N Engl J Med.* 2011;364(6):514-23.
- 8) Ito T, et al. Epidemiological Study of Gastroenteropancreatic Neuroendocrine Tumors in Japan. *J Gastroenterol.* 2010;45:234-43.